転移性去勢感受性前立腺がん(mCSPC)治療薬の世界市場:インサイト・疫学・市場予測

◆英語タイトル:Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Market Insight, Epidemiology and Market Forecast - 2030
◆商品コード:DELV20JU078
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年6月
◆ページ数:200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後最大10営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(78名様閲覧)USD6,950 ⇒換算¥729,750見積依頼/購入/質問フォーム
Three UserUSD10,425 ⇒換算¥1,094,625見積依頼/購入/質問フォーム
Site LicenseUSD13,900 ⇒換算¥1,459,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s “Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Metastatic Castration-Sensitive Prostate Cancer (mCSPC), historical and forecasted epidemiology as well as the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market report provides current treatment practices, emerging drugs, Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market share of the individual therapies, current and forecasted Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Metastatic Castration-Sensitive Prostate Cancer (mCSPC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Disease Understanding and Treatment Algorithm
The DelveInsight Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market report gives a thorough understanding of the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Metastatic Castration-Sensitive Prostate Cancer (mCSPC).

Treatment

It covers the details of conventional and current medical therapies available in the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market for the treatment of the condition. It also provides Metastatic Castration-Sensitive Prostate Cancer (mCSPC) treatment algorithms and guidelines in the United States, Europe, and Japan.

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology
The Metastatic Castration-Sensitive Prostate Cancer (mCSPC) epidemiology division provide insights about historical and current Metastatic Castration-Sensitive Prostate Cancer (mCSPC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Metastatic Castration-Sensitive Prostate Cancer (mCSPC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology

The epidemiology segment also provides the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Drug Chapters
Drug chapter segment of the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) report encloses the detailed analysis of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) treatment.

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) treatment.

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Outlook
The Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market in 7MM.

The United States Market Outlook

This section provides the total Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market size and market size by therapies in Japan is also mentioned.

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Metastatic Castration-Sensitive Prostate Cancer (mCSPC) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) emerging therapies.

Reimbursement Scenario in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
The report covers the descriptive overview of Metastatic Castration-Sensitive Prostate Cancer (mCSPC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market

Report Highlights
In the coming years, Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Castration-Sensitive Prostate Cancer (mCSPC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Metastatic Castration-Sensitive Prostate Cancer (mCSPC). Launch of emerging therapies will significantly impact the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Report Insights
Patient Population
Therapeutic Approaches
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Pipeline Analysis
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Report Key Strengths
11 Years Forecast
7MM Coverage
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions
Market Insights:

What was the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market share (%) distribution in 2017 and how it would look like in 2030?
What would be the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market size during the forecast period (2017-2030)?
At what CAGR, the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market is expected to grow in 7MM during the forecast period (2017-2030)?
What would be the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market outlook across the 7MM during the forecast period (2017-2030)?
What would be the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Metastatic Castration-Sensitive Prostate Cancer (mCSPC)?
What is the historical Metastatic Castration-Sensitive Prostate Cancer (mCSPC) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Metastatic Castration-Sensitive Prostate Cancer (mCSPC)?
Out of all 7MM countries, which country would have the highest prevalent population of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) during the forecast period (2017-2030)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
What are the current options for the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in the USA, Europe, and Japan?
What are the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)?
How many therapies are developed by each company for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) treatment?
How many are emerging therapies in mid-stage, and late stage of development for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) treatment?
What are the key collaborations (Industry – Industry, Industry – Academia), Mergers and acquisitions, licensing activities related to the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and their status?
What are the key designations that have been granted for the emerging therapies for Metastatic Castration-Sensitive Prostate Cancer (mCSPC)?
What are the global historical and forecasted market of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market
To understand the future market competition in the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market
To understand the future market competition in the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market

【レポートの目次】

1. Key Insights

2. Executive Summary of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

3. Competitive Intelligence Analysis for Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

4. Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Market Overview at a Glance

4.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Total Market Share (%) Distribution in 2017

4.2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Total Market Share (%) Distribution in 2030

5. Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treatment and Management

8.2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Seven Major Market Analysis

13.1. Key Findings

13.2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Size in 7MM

13.3. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Total Market Size in the United States

15.1.2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Total Market Size in Germany

15.3.2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Total Market Size in France

15.4.2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Total Market Size in Italy

15.5.2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Total Market Size in Spain

15.6.2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Total Market Size in the United Kingdom

15.7.2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Total Market Size in Japan

15.8.3. Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

Table 1 : 7MM Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology (2017-2030)

Table 2 : 7MM Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases (2017-2030)

Table 3 : Disease% Epidemiology in the United States (2017-2030)

Table 4 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in Germany (2017-2030)

Table 6 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in France (2017-2030)

Table 8 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in France (2017-2030)

Table 9 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in Italy (2017-2030)

Table 10 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in Spain (2017-2030)

Table 12 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in the UK (2017-2030)

Table 14 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in the UK (2017-2030)

Table 15 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in Japan (2017-2030)

Table 16 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in Japan (2017-2030)

Table 17 : Drug Name, Clinical Trials by Recruitment status

Table 18 : Drug Name, Clinical Trials by Zone

Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Table 20 : Region-wise Market Size in USD, Million (2017-2030)

Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Table 22 : United States Market Size in USD, Million (2017-2030)

Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Table 24 : Germany Market Size in USD, Million (2017-2030)

Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Table 26 : France Market Size in USD, Million (2017-2030)

Table 27 : France Market Size by Therapy in USD, Million (2017-2030)

Table 28 : Italy Market Size in USD, Million (2017-2030)

Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Table 30 : Spain Market Size in USD, Million (2017-2030)

Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Table 32 : United Kingdom Market Size in USD, Million (2017-2030)

Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Table 34 : Japan Market Size in USD, Million (2017-2030)

Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of tables is not exhaustive; the final content may vary

Figure 1 : 7MM Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology (2017-2030)

Figure 2 : 7MM Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases (2017-2030)

Figure 3 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in the United States (2017-2030)

Figure 4 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in Germany (2017-2030)

Figure 6 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in France (2017-2030)

Figure 8 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in Italy (2017-2030)

Figure 10 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in Spain (2017-2030)

Figure 12 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in the UK (2017-2030)

Figure 14 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in the UK (2017-2030)

Figure 15 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology in Japan (2017-2030)

Figure 16 : Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 17 : Drug Name, Clinical Trials by Recruitment status

Figure 18 : Drug Name, Clinical Trials by Zone

Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Figure 20 : Region-wise Market Size in USD, Million (2017-2030)

Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Figure 22 : United States Market Size in USD, Million (2017-2030)

Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Figure 24 : Germany Market Size in USD, Million (2017-2030)

Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Figure 26 : France Market Size in USD, Million (2017-2030)

Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)

Figure 28 : Italy Market Size in USD, Million (2017-2030)

Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Figure 30 : Spain Market Size in USD, Million (2017-2030)

Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)

Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Figure 34 : Japan Market Size in USD, Million (2017-2030)

Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of figures is not exhaustive; the final content may vary.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[転移性去勢感受性前立腺がん(mCSPC)治療薬の世界市場:インサイト・疫学・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆